M. Kulyk & Associates LLC Sells 11,801 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

M. Kulyk & Associates LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 88,666 shares of the biopharmaceutical company’s stock after selling 11,801 shares during the period. Gilead Sciences comprises 1.8% of M. Kulyk & Associates LLC’s portfolio, making the stock its 17th biggest holding. M. Kulyk & Associates LLC’s holdings in Gilead Sciences were worth $8,190,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bellevue Group AG boosted its position in Gilead Sciences by 18.2% in the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after purchasing an additional 7,093 shares during the last quarter. Quantinno Capital Management LP boosted its position in Gilead Sciences by 149.5% in the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after purchasing an additional 48,910 shares during the last quarter. McAdam LLC lifted its position in shares of Gilead Sciences by 16.7% during the 4th quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock valued at $2,344,000 after buying an additional 3,627 shares in the last quarter. Capital Investment Advisors LLC lifted its position in shares of Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after buying an additional 9,791 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in shares of Gilead Sciences by 3.9% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company’s stock valued at $13,132,000 after buying an additional 5,382 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the completion of the transaction, the chief financial officer now owns 169,061 shares in the company, valued at $17,597,559.49. The trade was a 1.46 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 293,356 shares of company stock valued at $29,166,240. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $117.41 on Friday. The company has a market cap of $146.22 billion, a P/E ratio of 317.32, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The business’s 50 day moving average price is $99.61 and its 200-day moving average price is $91.50. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $118.42.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.69%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is currently 854.05%.

Analyst Ratings Changes

GILD has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Finally, Piper Sandler lifted their price objective on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $104.24.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.